Half Year 2025 Benchmark Holdings PLC Earnings Call Transcript
Key Points
- Benchmark Holdings PLC (STU:31B) completed the Genetics deal, providing significant proceeds and leaving the company debt-free.
- The company has announced a proposal to return capital to shareholders, including a special dividend and a tender offer.
- Advanced Nutrition showed improved performance with a better product mix and increased adoption of new and existing nutrition solutions.
- The Health business area is now restructured, profitable, and cash positive, primarily based on Salmosan sales.
- Operational costs have been reduced by 13% in the first half, with further cost reductions expected from ongoing corporate streamlining.
- Revenues are down compared to last year, primarily due to changes in the Health business and ForEx headwinds in Advanced Nutrition.
- Adjusted EBITDA has decreased compared to the first half of last year, partly due to lower revenues and gross margins in Advanced Nutrition.
- The shrimp market continues to present challenging conditions for Advanced Nutrition.
- Sales in the Health business fell by 73% at a constant exchange rate, mainly due to the exit of Ectosan from the market.
- The company faces uncertainty related to announced US trade tariffs, which could impact future performance.
Good morning to all of you, and welcome to this half year presentation for Benchmark. As usual, I'm here with our CFO, Septima Maguire, and we are going to give you an update on our half year results for financial year '25. We will also briefly touch on the recent actions as well as the plan for return on capital to shareholders and future positioning of the group as it was announced on May 23.
We will follow the normal program, starting with the highlights, moving over to more granularity on the business. And also this time, of course, Septima will take you through the more detailed financials of the group. At the very end, there will be as usual an opportunity for Q&A. Starting with the highlights.
And let us start with the event that happened at the very end of Q2 and consequently led to actions and development after the quarter ended. As you all should be aware of, we completed the Genetics deal at the very end of the second quarter. This was an important milestone for us.
The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
